Compounded GLP-1 Medications in 2026: What the FDA Crackdown Means for You

What Are Compounded GLP-1 Medications?

Compounding is a longstanding pharmacy practice where a licensed pharmacist prepares a medication tailored to a specific patient's needs. A prescriber might request a different dosage strength or a formulation that removes a particular allergen. Hospitals and specialty pharmacies have been doing this for decades.

When semaglutide and tirzepatide landed on the FDA's drug shortage list between 2022 and 2024, compounding pharmacies were legally permitted to produce versions of these medications to help patients who couldn't access the brand-name products. That window created a large market, particularly because compounded versions cost significantly less.

These compounded products are not FDA-approved. They haven't gone through the clinical trial process or manufacturing review that the approval pathway requires. Instead, a compounding pharmacy fills them based on a prescriber's order, using bulk pharmaceutical ingredients. Quality controls depend on the individual pharmacy and its level of regulatory oversight.

Federal law creates two categories of compounding pharmacy. A 503A pharmacy fills individual prescriptions under state board of pharmacy oversight. 503B outsourcing facilities are FDA-registered, which means federal inspections and stricter manufacturing requirements than state-only oversight provides. If your provider discloses their pharmacy source, that distinction matters.

This foundation is useful because the regulatory landscape shifted after 2024. The enforcement actions described below grew out of specific problems in the compounded GLP-1 market during the shortage years, not concerns about compounding as a pharmacy practice.

What Is Actually Happening

The legal basis for widespread GLP-1 compounding ended when the FDA removed both medications from the shortage list:

• Tirzepatide: Shortage declared resolved December 19, 2024 (after an initial October determination and legal challenge)
• Semaglutide: Shortage declared resolved February 21, 2025

After the shortage resolution, compounding pharmacies had a grace period to wind down (60 days for 503A pharmacies, 90 days for 503B outsourcing facilities). Once those periods expired, routine compounding of commercially available doses of semaglutide and tirzepatide was no longer permitted.

Compounding can still occur in narrow circumstances. If a prescribing provider documents a clinical need for a specific patient (a different dose strength, an added ingredient, a preservative-free formulation), compounding may be appropriate. Affordability and patient preference alone are not sufficient justifications under current FDA guidance.

Enforcement Timeline

The regulatory response has come from multiple directions simultaneously. This is not a single agency acting alone.

In addition to federal enforcement, Eli Lilly has filed lawsuits against multiple telehealth companies and compounding pharmacies selling compounded tirzepatide, and Novo Nordisk has sued over compounded semaglutide. State attorneys general in Connecticut, Mississippi, and other states have taken separate enforcement actions against sellers marketing unapproved GLP-1 products.

Who Enforcement Is Targeting

Reading the headlines, it can sound like all compounded GLP-1 medications are under attack. The actual enforcement actions tell a more specific story. Looking at what the FDA, FTC, and state AGs have actually gone after reveals a pattern.

What Triggers Enforcement

• Marketing compounded products as "generic" or "equivalent to" brand-name drugs. The FDA's September 2025 warning letters specifically cited claims that compounded products are "generic versions" or contain the "same active ingredient" as FDA-approved drugs. Compounded medications are not FDA-approved and have not undergone the same testing.
• Quality control failures. Novo Nordisk's testing of compounded semaglutide products found impurities of up to 86% in injectable forms and 75% in oral forms. The FDA has reported dosing errors resulting in 5-20x the intended dose, leading to hospitalizations.
• Deceptive pricing. The FTC's case against NextMed centered on advertising $138-$188/month programs without disclosing that medication, labs, and consultations cost extra.
• Selling without prescriptions or proper medical oversight. Several warning letters targeted companies selling GLP-1 products online without requiring a valid prescription or clinical evaluation.
• Overseas and counterfeit products. The 38-state AG letter cited products entering the US from China, Turkey, and India containing unknown contaminants, incorrect dosages, and repackaged insulin falsely labeled as GLP-1 drugs.

What Is Not Being Targeted

Licensed telehealth providers that require a prescription from a licensed clinician, use compounding pharmacies with proper oversight, provide genuine medical support, and are transparent about what they offer and what it costs are operating in a different space than the entities receiving enforcement actions.

The distinction matters. Compounding pharmacies that comply with state pharmacy boards, maintain proper quality standards, and fill individual prescriptions based on clinical need operate under a different legal framework than companies mass-producing unregulated products for online sale without medical evaluation.

How to Tell the Difference

If you are considering a compounded GLP-1 medication, here is what to look for. These are not opinions. They come from the FDA's own guidance on what patients should verify.

Your Options in 2026

If you are currently on a compounded GLP-1 medication, or your provider has told you they can no longer supply it, here are the paths available.

Brand-Name Medications with Manufacturer Savings

Both Novo Nordisk and Eli Lilly have introduced self-pay programs that bring costs well below list price:

• Wegovy® (semaglutide injection): $199/month for starter doses, $349/month for maintenance through NovoCare
• Oral Wegovy® (semaglutide pill): Approved December 2025. $149/month starter, $299/month maintenance through NovoCare
• Zepbound® (tirzepatide injection): $299/month for starter doses, $449/month for maintenance through LillyDirect single-dose vials

These are still more expensive than most compounded options, but they are FDA-approved medications with verified potency and quality.

Insurance Coverage

If you have commercial insurance that covers GLP-1 medications for weight management, manufacturer savings cards can reduce your copay to as low as $25/month for either Wegovy® or Zepbound®. Coverage varies significantly by plan. Prior authorization is typically required, which your prescribing provider handles. If your insurance denies coverage, our guide on appealing GLP-1 insurance denials walks through the process and what to do next.

Licensed Telehealth Providers

Several telehealth providers connect patients with licensed clinicians who can evaluate your situation and prescribe the appropriate medication. Some providers offer both brand-name and compounded options where available. Others focus exclusively on one or the other. The provider landscape continues to evolve as regulations change.

When choosing a provider, the verification checklist above applies. A licensed provider with transparent pricing, clinical support, and identified pharmacy sources is operating differently from the entities facing enforcement actions.

What to Watch For Going Forward

The regulatory landscape is still evolving. Several developments could change the picture:

Congressional Action

The SAFE Drugs Act (H.R. 6509), introduced December 2025, would require compounding pharmacies filling more than 20 GLP-1 prescriptions per month for out-of-state patients to submit detailed reports to federal regulators. It would also codify the definition of "essentially a copy" and require pre-compounding inspections. The bill is in committee as of February 2026.

Legal Challenges Continue

The Outsourcing Facilities Association has sued the FDA over both the tirzepatide and semaglutide shortage resolutions. Courts have generally sided with the FDA so far, but legal challenges continue. A ruling that reverses either shortage determination would change compounding access immediately.

Manufacturer Pricing May Continue Dropping

Both Novo Nordisk and Eli Lilly have reduced cash-pay pricing multiple times since late 2024. LillyDirect lowered Zepbound vial prices in December 2025. NovoCare launched self-pay programs in November 2025. If this trend continues, the price gap between brand-name and compounded narrows further.

The Bottom Line

The compounded GLP-1 market is under pressure from federal agencies, state regulators, brand-name manufacturers, and new legislation all at once. Most of the enforcement so far has focused on unregulated products, misleading marketing, and quality control failures.

For patients, the most important thing is working with a licensed provider who requires a prescription, provides clinical support, and is transparent about what they offer. Whether you end up on a brand-name medication or a compounded version where clinically appropriate depends on your health situation, insurance coverage, and what your provider recommends.

This is not a situation where one headline tells the whole story. Talk to your provider about your specific options.

How We Evaluate Providers

When reviewing telehealth providers, we look at licensing, pricing transparency, pharmacy sourcing, and clinical support quality. We also confirm whether they accept insurance. We disclose our partnerships and maintain editorial independence in our evaluations. See our advertiser disclosure for details.

Featured Programs

These programs include licensed clinician consultations. Compare what each offers.

Sources

1. FDA. FDA's concerns with unapproved GLP-1 drugs used for weight loss. Updated February 2026.
2. FDA. FDA intends to take action against non-FDA-approved GLP-1 drugs. February 6, 2026.
3. Wilson Sonsini. FDA sends warning letters to more than 50 GLP-1 compounders and manufacturers. September 2025.
4. FTC. FTC takes action against NextMed over misleading prices and fake testimonials. July 2025.
5. NAAG. 38 state attorneys general urge FDA action on counterfeit GLP-1 drugs. February 2025.
6. Connecticut AG. Crackdown on bootleg GLP-1 weight loss drugs. 2025.
7. US Congress. SAFE Drugs Act of 2025 (H.R. 6509). Introduced December 2025.
8. Pharmacy Times. Navigating FDA compounding regulations. 2025.
9. McDermott Will & Emery. Court backs FDA in tirzepatide compounding case. 2025.
10. FDA MedWatch. Dosing errors with compounded semaglutide.